MedTech

FDA approves Freenome colorectal cancer blood test

Abbott will pay Freenome $100 million as part of a 2025 deal covering the test’s U.S. commercialization in adults 45 and older who are at average risk for colorectal cancer.

Ben Adams Jul 27, 2026 10:29am

Labcorp launches ‘Health Panel’ to seek out multiple diseases

Jul 27, 2026 8:00am

FDA clears J&J's surgical robot for ‘the next era in surgery’

Jul 23, 2026 8:27am

Roche Diagnostics growth remains muted amid China headwinds

Jul 23, 2026 8:13am

HHS headquarters as seen on April 02 2025

NIH joins Trump’s $5B AI mission with biomedical research push

Jul 22, 2026 2:43pm

Roche taps Foundation chief as North America Diagnostics lead

Jul 21, 2026 4:32am